Solid Biosciences’ gene therapy

Solid GT Ground-breaking gene therapy platform for Duchenne (IGNITE DMD Clinical Trial) In May 2026, Solid Biosciences announced that the first participant had been dosed in the Phase III clinical study of its next-generation gene therapy, SGT-003. The patient was...

HT-100

HT-100 Targeting muscle fibrosis HT-100 is a drug aimed at halting or even reversing fibrosis, the muscle scarring in Duchenne boys. It is intended to benefit all boys, regardless of type of mutation. We were part of a consortium of 12 Duchenne patient foundations...

Vamorolone

Vamorolone Alternative to existing steroids for all with Duchenne In January 2024, vamrolone became the first drug for all people with Duchenne muscular dystrophy to be approved in the US, the EU and the UK. In December 2024, it was approved by NICE for use on the...

Ringo

Ringo Dystrophic dogs provide insights into Duchenne research The Duchenne Research Fund supported Professor Mayana Zatz, Natássia Vieira and their team at the University of Sao Paulo, Brazil, who investigated why two golden retrievers showed no severe symptoms...